Tuesday, July 27, 2021
News

Subject Expert Committee gives nod to Covaxin for Phase 2, 3 trials on children aged 2 to 18 years

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | May 12, 2021 1:44:19 PM IST
The Subject Expert Committee (SEC) has given a nod to Bharat Biotech''s Covaxin for Phase 2 and 3 human clinical trials on children aged between two to eight years old, sources confirmed on Wednesday.

Covaxin is one of the two vaccines being manufactured in India at present and has been developed by Bharat Biotech in association with the Indian Council of Medical Research and the National Institute of Virology.

The firm on Tuesday informed that it has been supplying its COVID-19 vaccine directly to 18 states since May 1.

"Unflinching in our efforts, we will continue the steady supply of our vaccine," the company tweeted.

Maharashtra, Madhya Pradesh, Bihar, Uttar Pradesh, West Bengal and Assam are among the 18 states where the company has been supplying the vaccines directly.

Following the Government of India directives, the Hyderabad-based vaccine maker had earlier announced that it will provide Covaxin to state government hospitals at the rate of Rs 400 per dose. (ANI)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Mamata Banerjee meets PM Modi...
Mamata Banerjee to meet Sonia Gandhi at ...
Centre issued advisory to check illegal ...
Tamil Nadu BJP chief pays tribute to APJ...
HC seeks fresh status report from Delhi ...
Pegasus row: Manish Tewari gives adjourn...
More...    
 
 Top Stories
Iran busts terror group, arrests 36... 
Tata Communications launches IZOTM ... 
Antibodies drop 50% in 3 months of ... 
Kerala Bishop offers sops for famil... 
Odisha police busts newborn traffic... 
TN to micromanage 11 districts with... 
Appeal to rethink as Parliament mea... 
Mani Ratnam's 'Navarasa' trailer ou...